Indivior reported 1.2B in Assets for its fiscal semester ending in March of 2026.





Assets Change Date
AstraZeneca USD 115.83B 1.82B Jun/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
West Pharmaceutical Services USD 4.08B 33.4M Jun/2026